Ranibizumab biosimilar (Reliance Life Sciences Group)

雷珠单抗生物类似药（Reliance Life Sciences Group）

Report date: 2023/04/10 09:57:23

Base Information

Drug NameRanibizumab biosimilar (Reliance Life Sciences Group)

Drug Alias Name雷珠单抗生物仿制药（Reliance Life Sciences Group）RanizuRelR-TPR-024

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragmentBiologics > Biosimilar

Mechanisms of ActionAngiogenesis inhibitorsVascular endothelial growth factor A inhibitors

TargetsVascular endothelial growth factor A

Therapy Area/IndicationsMacular Degeneration

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesReliance Life Sciences

China Registration ClassN/A

Develop Information

Active CompaniesReliance Life Sciences

Inactive CompaniesN/A

Active IndicationsMacular Degeneration

Inactive IndicationsN/A

Other Information

ATC CodeS01LA04